Cytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cantor Fitzgerald Remains Bullish on Cytokinetics (CYTK)
February 17, 2017 7:50 AM ESTCantor Fitzgerald reiterated an Overweight rating and $21.00 price target on Cytokinetics (NASDAQ: CYTK). 4Q16 fully diluted EPS was $0.16, which was better than ($0.43) forecasts due to the inclusion of a $26 mln payment from Amgen for omecamtiv mecarbil.
Analyst Mara Goldstein commented, "We rate CYTK Overweight... More
FBR Capital Reiterates Outperform on Cytokinetics (CYTK) Following 4Q
February 17, 2017 7:17 AM ESTFBR Capital reiterated an Outperform rating and $24.00 price target on Cytokinetics (NASDAQ: CYTK) following the company's 4Q earnings report.
Analyst Vernon Bernardino commented, "On February 16, CYTK announced 4Q16 results dominated by the achievement of significant milestones in its cardiac muscle-directed clinical program... More
Piper Jaffray Reiterates Overweight Rating and $15 PT on Cytokinetics (CYTK) Following 4Q16 Results
February 17, 2017 6:05 AM ESTPiper Jaffray analyst Charles Duncan reiterates Overweight rating and $15 price target on Cytokinetics Inc. (NASDAQ: CYTK), suggesting the companys cash position provides strong 12 month upside potential, as 2016 fourth quarter results include $33 million in revenues and $156 million in year-end cash.
Duncan comments, "On Thursday AMC... More
